Osobennosti klinicheskogo techeniya invazivnogo dol'kovogo raka molochnoy zhelezy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the characteristics of lobular invasive carcinoma (LIC) compared with ductal invasive carcinoma in breast cancer. Despite more frequent incidence of ductal carcinoma, LIC occurs in older patients and is characterized by several more favorable prognostic features (positive estrogen and/or progesterone receptors, negative HER2 status, low Ki 67 levels, and a low degree of malignancy. On the other hand, the pattern of growth of the primary tumor in LIC and complexity of radiological diagnosis determine relatively late detection of the disease. In some cases, the problem includes a quite unusual for breast cancer localization of metastases in ovaries, peritoneum and gastrointestinal tract. The clinical observation of the patient 57 years old with LIC illustrating features of the course of this form of cancer is presented. Based on the results of large clinical trials, approaches to the treatment of LIC are discussed. It is stated that the best option of adjuvant endocrine therapy for menopausal patients with luminal, HER2 negative LIC is the use of aromatase inhibitors, in particular - letrozole.

Full Text

Restricted Access

References

  1. Франк Г.А., Данилова Н.В., Андреева Ю.Ю. и др. Классификация опухолей молочной железы ВОЗ 2012 года. Архив патологии. 2013;2:53-63.
  2. Hussien M., Lioe T.F., Finnegan J., et al. Surgical treatment for invasive lobular carcinoma of the breast. Breast. 2003;12:23-35.
  3. Stivalet A., Luciani A., Pigneur F., et al. Invasive lobular carcinoma of the breast: MRI pathological correlation following bilateral total mastectomy. Acta Radiol. 2012;53:367-75.
  4. Fernndez B, Paish E.C., Green A.R., et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J. Clin. Pathol. 2011;64: 995-1000.
  5. Dedes K.J., Fink D. Clinical presentation and surgical management of invasive lobular carcinoma of the breast. Breast Dis. 2009;30:31-7.
  6. Grazia A, Valerie J.B., Clarketal G.M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical out come. Breast Cancer Res. 2004;6:R149-56.
  7. Girardi V., Carbognin G., Camera L., et al. Multifocal, multicentric and contralateral breast cancers: breast MR imaging in the preoperative evaluation of patients with newly diagnosed breast cancer. Radiol. Med. 2011; 116:1226-38.
  8. Wasif N., Maggard M.A., Ko C.Y., et al. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann. Surg. Oncol. 2010;17:1862-69.
  9. Wallace A.S., Xiang D., Hockman L., et al. Synchronous lobular carcinoma in situ and invasive lobular cancer: Marker or precursor for invasive lobular carcinoma. EJSO. 2014;40(10):1245-49.
  10. Biglia N., Mariani L., Sgro L., et al. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr. Relat. Cancer. 2007;14:549-67.
  11. Guiu S., Wolfer A., Jacot W., et al. Invasive lobular breast cancer and its variants: How special are they forsystemic therapy decisions? Crit. Rev. Oncol. Hematol. Published Online: July 29, 2014; DOI: http://dx.doi.org/10.1016/j.crit-revonc.2014.07.003
  12. Rakha E.A., Ellis I.O. Lobular breast carcinoma and its variants. Semin. Diagn. Pathol. 2010;27:49-61.
  13. Nagao T., Kinoshita T., Hojo T., et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21:289-95.
  14. Dixon J.M., Renshaw L., Dixon J., et al. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res. Treat. 2011;130:871-77.
  15. Katz A., Saad E.D., Porter P., et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007;8:55-62.
  16. Colleoni M., Russo L., Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast. 2011;20(Suppl 3):S153-57. длительности адъювантной эндокри-нотерапии до 10 лет и более.
  17. Brunello E., Brunelli M., Manfrin E., et al. Classical lobular breast carcinoma consistently lacks topoisomerase-IIa gene amplification: implications for the tailored use of anthracycline -based chemotherapies. Histopathology. 2012;60:482-88.
  18. Colleoni M., Rotmensz N., Maisonneuve P., et al. Outcome of special types of luminal breast cancer. Ann. Oncol. 2012;23:1428-36.
  19. Mhuircheartaigh J.N., Curran C., Hennessy E., et al. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br. J. Surg. 2008;95: 827-33.
  20. Rakha E.A., El-Sayed M.E., Powe D.G., et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur. J. Cancer. 2008;44:73-83.
  21. Pestalozzi B.C., Zahrieh D., Mallon E., et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J. Clin. Oncol. 2008;26:3006-14.
  22. Metzger O., Giobbie-Hurder A., Mallon E., et al. 35th Annual San Antonio Breast Cancer Symposium. 2012. Ab. S1-1 + Ab. P01-02-05.
  23. Regan M.M., Neven P., Giobbie-Hurder A., et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011;12:1101-08.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies